Comparison of mean platelet volume in patients with psoriasis and healthy individuals
Keywords:
Psoriasis, platelet activation, mean platelet volume, cardiovascular complicationsAbstract
Objective To compare mean platelet volume in patients with psoriasis and healthy individuals. Methodology This case control study was conducted in outpatients department and indoor of department of Dermatology, DHQ Hospital, Faisalabad. The duration of study was six months. Thirty consecutive patients of psoriais, 20 to 60 years of age and thirty age and gender matched healthy individuals were selected. 2cc venous blood sample from each subject was sent to the pathology laboratory of DHQ Hospital. Mean platelet volume (MPV) was measured as a part of blood complete analysis in Medonic M series Haematology analser. Results MPV was found higher in the patients of psoriasis as compared to the healthy individuals. The mean value of MPV in the case group was 8.24±1.22 fl, whereas in the control group, it was 7.29±0.77 fl (p<0.05). Conclusion The study demonstrated that mean platelet volume is increased in patients with psoriasis as compared to healthy individuals. Such patients are at an increased risk of cardiovascular complications.References
Mehta NN, Yu Y, Pinnelas R et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124:775.e1-6.
Tamagawa-Mineoka R, Katoh N, Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol. 2010;62:621-6.
Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248-57.
Yilmaz MB, Cihan G, Guray Y et al. Role of mean platelet volume in triagging acute coronary syndromes. J Thromb Thrombolysis. 2008;26:49-54.
Tekbas E, Kara AF, Ariturk Z et al. Mean platelet volume in predicting short- and long-term morbidity and mortality in patients with or without ST-segment elevation myocardial infarction. Scand J Clin Lab Invest. 2011;71:613-9.
Canpolat F, Akpinar H, EskioÄŸlu F. Mean platelet volume in psoriasis and psoriatic arthritis. Clin Rheumatol. 2010;29:325-8.
Khurshid K, Ullah I, Rani Z et al. Efficacy and safety of narrowband UVB in the treatment of chronic plaque psoriasis. Ann King Edward Med Uni. 2010;16:31-3.
Ejaz A, Raza N, Iftikhar N et al. Presentation of early onset psoriasis in comparison with late onset psoriasis: a clinical study from Pakistan. Indian J Dermatol Venereol Leprol. 2009;75:36-40.
Lewis BJ, Rajpara S, Haggart AM et al. Predominance of activated, clonally expanded T helper type 17 cells within the CD4(+) T cell population in psoriatic lesions. Clin Exp Immunol. 2013;173:38-46.
Armstrong AW. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? JAMA. 2013;309:2043-4.
Xu N, Meisgen F, Butler LM et al. MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine/threonine kinase 40. J Immunol. 2013;190:678-88.
Ghalamkarpour F, Saeedi M, Hedayati M, Maarefat A. Soluble E-selectin and P-selectin serum levels in patients with psoriasis compared to healthy controls. Iranian Dermatol. 2010;13:9-10.
Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost. 2009;35:313-24.
